


# ARCHER® **FUSIONPlex**® Lung Kit

The Archer® FusionPlex® Lung Kit is a targeted next-generation sequencing (NGS) assay to detect EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations in 14 key gene targets associated with lung cancer. The kit is powered by Archer's proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints.


## Highlights



**Focused fusion detection**  
Small panel to interrogate discrete oncogenic fusions



**Sample versatility**  
Purpose-built for low-input FFPE samples



**Splice variants**  
Identify expressed EGFRvIII and MET exon 14 skipping events



**Lyophilized workflow**  
Reduce turn-around time and eliminate master mixes

## Specifications

14

Gene targets

≥10ng

Input nucleic acid required\*

500K

Recommended # of reads

2.5h

Hands-on time

9h


Total time

Illumina®

Platform

\*Input recommendations for FFPE samples vary depending on Archer Preseq® RNA QC score; 50ng input recommended in absence of PreSeq screening

# Gene targets



**Legend**  
◆ SNV or indel  
● Fusion, splicing or exon skipping

## Product information

### ILLUMINA

AB0121 — 8 reactions

AB0128 — 16-reaction starter

AB0129 — 48 reactions



One size <sup>does not</sup> fits ~~all~~.

Want to customize? Combine any of hundreds of wet lab-validated designs or modify an existing Archer panel with **Archer Assay Designer**, the premiere online design tool to build an assay that fits your exact requirements.

Learn more at [archerdx.com/solid-tumor](https://archerdx.com/solid-tumor)



**RUO** For research use only. Not for use in diagnostic procedures.

©2018 ArcherDX, Inc. All rights reserved. Archer®, FusionPlex®, PreSeq® and AMP™ are trademarks of ArcherDX, Inc. Illumina® is a registered trademark of Illumina, Inc.

APM052.A